Doctors and parents celebrated the major advances that came in 2023 to treat respiratory syncytial virus (RSV), which sends up to 80,000 children under age five to the hospital each year in the U.S. This year, the U.S. Food and Drug Administration approved two critical ways to reduce the risk of RSV in young kids: a vaccine for pregnant mothers that can protect newborns, and a drug treatment for babies under one year.

In a study published in the New England Journal of Medicine, researchers report encouraging real-world data that show how effective the drug treatment, nirsevimab (brand name: Beyfortus), can beคำพูดจาก เว็บปั่นสล็อต. The study, which wa…